Literature DB >> 11272150

Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice.

T Masaki1, H Yoshimatsu, S Chiba, T Watanabe, T Sakata.   

Abstract

Leptin resistance has recently been confirmed not only in animal obese models but in human obesity. Evidence is rapidly emerging that suggests that activation of histamine signaling in the hypothalamus may have substantial anti-obesity and antidiabetic actions, particularly in leptin-resistant states. To address this issue, effects of central, chronic treatment with histamine on food intake, adiposity, and energy expenditure were examined using leptin-resistant obese and diabetic mice. Infusion of histamine (0.05 pmol x g body wt(-1) x day(-1)) into the lateral cerebroventricle (i.c.v.) for 7 successive days reduced food intake and body weight significantly in both diet-induced obesity (DIO) and db/db mice. Histamine treatment reduced body fat weight, ob gene expression, and serum leptin concentration more in the model mice than in pair-fed controls. The suppressive effect on fat deposition was significant in visceral fat but not in subcutaneous fat. Serum concentrations of glucose and/or insulin were reduced, and tests for glucose and insulin tolerance showed improvement of insulin sensitivity in those mice treated with histamine compared with pair-fed controls. On the other hand, gene expression of uncoupling protein (UCP)-1 in brown adipose tissue and UCP-3 expression in white adipose tissue were upregulated more in mice with i.c.v. histamine infusion than in the pair-fed controls. These upregulating effects of histamine were attenuated by targeted disruption of the H1-receptor in DIO and db/db mice. Sustained i.c.v. treatment with histamine thus makes it possible to partially restore the distorted energy intake and expenditure in leptin-resistant mice. Together, i.c.v. treatment with histamine contributes to improvement of energy balance even in leptin-resistant DIO and db/db mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11272150     DOI: 10.2337/diabetes.50.2.376

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

Review 1.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

2.  Effects of fasting on hypoxic ventilatory responses and the contribution of histamine H1 receptors in mice.

Authors:  Yasuyoshi Ohshima; Michiko Iwase; Masahiko Izumizaki; Hideaki Nakayama; Ichiei Narita; Ikuo Homma
Journal:  J Physiol Sci       Date:  2010-12-25       Impact factor: 2.781

3.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

Authors:  R Coccurello; A Caprioli; O Ghirardi; R Conti; B Ciani; S Daniele; A Bartolomucci; A Moles
Journal:  Psychopharmacology (Berl)       Date:  2006-05-13       Impact factor: 4.530

4.  Dipsogenic potentiation by sodium chloride but not by sucrose or polyethylene glycol in tuberomammillary-mediated polydipsia.

Authors:  J Mahía; A Bernal; A Puerto
Journal:  Exp Brain Res       Date:  2007-07-14       Impact factor: 1.972

5.  H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice.

Authors:  Vineesh V Raveendran; Karen M Kassel; Donald D Smith; James P Luyendyk; Kurt J Williams; Rachel Cherian; Gregory A Reed; Colleen A Flynn; Iván L Csanaky; Andrew L Lickteig; Matthew J Pratt-Hyatt; Curtis D Klaassen; Kottarappat N Dileepan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-22       Impact factor: 4.052

6.  Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype.

Authors:  Kazuhiko Takahashi; Hiroaki Suwa; Tomoo Ishikawa; Hidehito Kotani
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 7.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

8.  Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.

Authors:  Michael Poyurovsky; Camil Fuchs; Artashez Pashinian; Adva Levi; Ronit Weizman; Abraham Weizman
Journal:  Psychopharmacology (Berl)       Date:  2012-12-13       Impact factor: 4.530

9.  Expression patterns of corticotropin-releasing factor, arginine vasopressin, histidine decarboxylase, melanin-concentrating hormone, and orexin genes in the human hypothalamus.

Authors:  David M Krolewski; Adriana Medina; Ilan A Kerman; Rene Bernard; Sharon Burke; Robert C Thompson; William E Bunney; Alan F Schatzberg; Richard M Myers; Huda Akil; Edward G Jones; Stanley J Watson
Journal:  J Comp Neurol       Date:  2010-11-15       Impact factor: 3.215

10.  Role of hepcidin in murine brain iron metabolism.

Authors:  S-M Wang; L-J Fu; X-L Duan; D R Crooks; P Yu; Z-M Qian; X-J Di; J Li; T A Rouault; Y-Z Chang
Journal:  Cell Mol Life Sci       Date:  2009-11-08       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.